The US Food and Drug Administration takes a “more pragmatic” approach to cell and gene therapy development, which provides companies with a “less stringent pathway” to show that their product has potential, according to Shirley Bartido, Takeda’s director of global regulatory affairs, cell therapy oncology.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?